Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRD-740 (Primary)
Indications Heart failure
Focus Proof of concept; Therapeutic Use
Acronyms CARDINAL-HF
Sponsors Cardurion Pharmaceuticals

Most Recent Events

02 Sep 2024 Results presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
11 May 2024 Results presented at the Annual Congress of the Heart Failure Association of the European Society of Cardiology, taking place on May 11-14 in Lisbon, Portugal.
11 May 2024 Primary endpoint has been met. (Part A: The change from baseline (Day -1) in plasma cGMP at Week 4.)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com